| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 2962 | 2020 |
| MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease Gastroenterology 158 (7), 1999-2014.e1., 2020 | 2443 | 2020 |
| Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis Z Younossi, F Tacke, M Arrese, B Chander Sharma, I Mostafa, ... Hepatology 69 (6), 2672-2682, 2019 | 1570 | 2019 |
| A multisociety Delphi consensus statement on new fatty liver disease nomenclature ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, ... Hepatology 78 (6), 1966-1986, 2023 | 1037 | 2023 |
| Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis G Musso, R Gambino, JH Tabibian, M Ekstedt, S Kechagias, ... PLoS medicine 11 (7), e1001680, 2014 | 704 | 2014 |
| Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates Z Younossi, M Stepanova, JP Ong, IM Jacobson, E Bugianesi, A Duseja, ... Clinical gastroenterology and hepatology 17 (4), 748-755. e3, 2019 | 664 | 2019 |
| The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease M Eslam, SK Sarin, VWS Wong, JG Fan, T Kawaguchi, SH Ahn, ... Hepatology international 14, 889-919, 2020 | 566 | 2020 |
| FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation … PN Newsome, M Sasso, JJ Deeks, A Paredes, J Boursier, WK Chan, ... The lancet Gastroenterology & hepatology 5 (4), 362-373, 2020 | 527 | 2020 |
| Advancing the global public health agenda for NAFLD: a consensus statement JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, ... Nature Reviews Gastroenterology & Hepatology 19 (1), 60-78, 2022 | 427 | 2022 |
| Apoptosis: why and how does it occur in biology? E Ulukaya, C Acilan, Y Yilmaz Cell biochemistry and function 29 (6), 468-480, 2011 | 305 | 2011 |
| is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions? Y Yilmaz Alimentary pharmacology & therapeutics 36 (9), 815-823, 2012 | 289 | 2012 |
| Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis FE Mózes, JA Lee, EA Selvaraj, ANA Jayaswal, M Trauner, J Boursier, ... Gut 71 (5), 1006-1019, 2022 | 272 | 2022 |
| NASH in lean individuals R Younes, E Bugianesi Seminars in liver disease 39 (01), 086-095, 2019 | 228 | 2019 |
| Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease Y Yilmaz, F Eren, O Yonal, R Kurt, B Aktas, CA Celikel, O Ozdogan, ... European journal of clinical investigation 40 (10), 887-892, 2010 | 227 | 2010 |
| Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis Y Yilmaz, E Dolar, E Ulukaya, S Akgoz, M Keskin, M Kiyici, S Aker, ... World journal of gastroenterology: WJG 13 (6), 837, 2007 | 221 | 2007 |
| Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease Y Yilmaz, O Yonal, R Kurt, YO Alahdab, F Eren, O Ozdogan, CA Celikel, ... Scandinavian journal of gastroenterology 46 (1), 91-97, 2011 | 176 | 2011 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 160 | 2022 |
| Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis Y Yilmaz, O Yonal, O Deyneli, CA Celikel, C Kalayci, DG Duman Acta gastro-enterologica Belgica 75, 240-4, 2012 | 152 | 2012 |
| The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? JV Lazarus, HE Mark, M Villota-Rivas, A Palayew, P Carrieri, M Colombo, ... Journal of hepatology 76 (4), 771-780, 2022 | 151 | 2022 |
| Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic … Y Yilmaz, O Yonal, R Kurt, M Bayrak, B Aktas, O Ozdogan Hepatitis monthly 11 (2), 103, 2011 | 133 | 2011 |
